Evoke Pharma Shares Soar 133% on In-Licensing Strategy and GIMOTI Momentum

Company Introduction

Evoke Pharma Inc. (NASDAQ: EVOK), founded in 2007 and based in Solana Beach, California, is a biotechnology research company focused on gastrointestinal diseases. Its lead product, GIMOTI™ (metoclopramide) nasal spray, provides a non-oral treatment option for diabetic gastroparesis, a condition characterized by delayed gastric emptying and symptoms such as nausea, abdominal pain, bloating, and vomiting.

Corporate Structure

With a workforce of 2–10 employees, Evoke Pharma has a leadership team with significant industry experience:

• Matthew J. D’Onofrio, MBA, BS, co-founder and Chief Executive Officer, has over 30 years of experience in the pharmaceutical industry and guided GIMOTI from development through its U.S. launch in 2020.
• Mark Kowieski, CPA, Chief Financial Officer since 2024, joined Evoke in 2022 as Vice President of Finance and oversees SEC reporting, budgeting, and support for commercial strategy.
• Marilyn R. Carlson, D.M.D., M.D., has served as the Chief Medical Officer since joining in 2007, directing clinical and regulatory activities including trials that supported FDA approval of GIMOTI.
• Chris Quesenberry, Chief Commercial Officer for GIMOTI, brings over 30 years of experience in pharmaceutical sales and marketing, partnering with EVERSANA™ for distribution and access.

Gastroenterology by Kevin Kandlbinder

Developments and News

On November 4, 2025, Evoke Pharma shares closed at $10.7101, reflecting a 133.34% gain on volume of 962,015 shares traded on the NASDAQ. This increase followed investor interest in the company's strategy to in-license or acquire additional gastroenterology assets and in its commercial infrastructure established for GIMOTI. Since launching its first product in 2020, Evoke has been in discussions to develop novel compounds targeting the erratic absorption of oral medications in patients with gastroparesis.

Financial and Strategic Analysis

The stock’s 133.34% increase on November 4 highlights market interest in Evoke’s growth potential. Although full-year revenue figures are not publicly disclosed, the company reported a year-over-year increase in net product sales, reaching $3.8 million, supported by its partnership with EVERSANA for integrated sales, marketing, and reimbursement services. Financial controls have been improved under CFO Mark Kowieski, while CEO Matthew D’Onofrio's experience in business development and regulatory strategy has influenced Evoke’s pipeline approach to licensing. Current capital allocation focuses on funding the clinical development of in-licensed assets and expanding the specialty pharmacy network.

Market Position and Industry Context

Evoke Pharma operates in the gastroenterology segment, with GIMOTI as the only FDA-approved nasal spray for diabetic gastroparesis. The company’s small size enables agile decision-making, and collaborations with EVERSANA and Omnicell provide enhanced patient access through major gastroenterology practices. The gastrointestinal therapy market is competitive, but Evoke’s emphasis on non-oral delivery and its intellectual property related to metoclopramide formulations distinguishes it from oral agents that have been approved since 1979.

tl;dr

On November 4, 2025, Evoke Pharma’s stock rose 133.34% to $10.71 on NASDAQ due to investor attention on its plan to in-license gastrointestinal therapies and the ongoing commercialization of GIMOTI launched in 2020. The company continues to leverage its partnership with EVERSANA for commercialization and is pursuing additional assets that incorporate novel delivery technologies. Future milestones include potential licensing agreements and clinical data readouts for expanded gastroparesis treatments.